Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Says it is Fielding Acquisition Offers

NEW YORK – Qiagen said on Friday afternoon that it has received several "conditional, non-binding indications of interest" from potential merger or acquisition partners.

As such, the company has begun a review of potential strategic alternatives, it said.

"The supervisory board and the management board of Qiagen, in accordance with their fiduciary duties and as part of the review of potential strategic alternatives, are starting discussions with interested parties," the company said in a statement. "These discussions aim to explore potential strategic alternatives that could provide greater value creation opportunities than the already strong standalone growth prospects for the company, taking into consideration the interests of Qiagen's stakeholders including its shareholders."

The company also noted that there is no guarantee or certainty that these discussions will lead to a recommended firm offer to all shareholders of the company.

The announcement comes in the wake of a media report on Wednesday that Thermo Fisher Scientific had approached Qiagen about a potential buyout. Qiagen officials had declined to comment at that time.

Qiagen's shares surged nearly 10 percent in heavy trading on the New York Stock Exchange to $35.45 on Wednesday following the Thermo Fisher buyout speculation, after having reached a three-year low of $25.42 on Oct. 8 in the wake of lowered full-year revenue guidance, news that it had discontinued its sequencer development, and a CEO transition.

Qiagen's shares on Friday closed up nearly 9 percent at $40.56.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.